Atlas Capital Advisors Inc. Makes New Investment in Elevance Health, Inc. $ELV

Atlas Capital Advisors Inc. bought a new position in Elevance Health, Inc. (NYSE:ELV) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 3,503 shares of the company’s stock, valued at approximately $1,228,000.

Other institutional investors have also recently made changes to their positions in the company. Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Elevance Health in the 4th quarter worth approximately $5,941,000. Victory Capital Management Inc. raised its position in shares of Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after acquiring an additional 109,462 shares in the last quarter. Bright Rock Capital Management LLC bought a new position in shares of Elevance Health in the 4th quarter worth approximately $7,362,000. Prana Capital Management LP increased its position in Elevance Health by 798.9% during the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after buying an additional 45,889 shares in the last quarter. Finally, Loews Corp increased its position in Elevance Health by 107.5% during the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock valued at $35,543,000 after buying an additional 57,000 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

ELV has been the subject of a number of analyst reports. Truist Financial raised their price objective on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Morgan Stanley raised their price objective on Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Jefferies Financial Group reduced their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Bank of America raised their price objective on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. Finally, Leerink Partners set a $364.00 price objective on Elevance Health in a research report on Thursday, April 23rd. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $416.11.

Elevance Health Stock Performance

ELV stock opened at $403.74 on Monday. The company has a market cap of $87.68 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock’s fifty day moving average price is $366.62 and its 200-day moving average price is $344.97.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period last year, the business posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is currently owned by company insiders.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.